MarketBeat
22 Sept 2026, 03:02 UTC · 3h ago
Verdict
Headline takes no side. We score VSTM +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Verastem expects to provide clinical data on its KRAS G12D inhibitor VS-7375 in October, including cohorts of over 20 patients in pancreatic and lung cancer.
Newsays "expects to provide data on VS-7375 in October"
So whatSuccess in these cohorts would likely trigger a valuation re-rating ahead of the H1 2027 Phase III transition.
More positive than 92% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
The confirmatory Phase III RAMP 301 study for the AVMAPKI FAKZYNJA CO-PACK is fully enrolled with a readout expected in 2027.
Priced inno timing evidence for the enrollment status
So whatA positive readout would allow expansion into the 70% KRAS wild-type ovarian cancer market.
More positive than 85% of claims this week
Verastem plans to establish three frontline Phase III programs for VS-7375 in the first half of 2027.
Newexecutives outlined priorities at an H.C. Wainwright event
So whatThe shift to frontline studies represents a significant increase in R&D spend and clinical risk for FY2027.
More positive than 76% of claims this week
The RAMP 205 study of avutametnib and defactinib with gemcitabine/Abraxane in frontline metastatic pancreatic cancer showed a 52% response rate and ~1 year overall survival.
Priced inanalysis of study results at an event
So whatThese results provide a baseline for the company's belief that 40% of pancreatic cancers are G12D-driven.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is advancing multiple clinical programs and launching a new commercial product with positive early trial data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
VSTM hasn't traded since this ran. Last close $7.99 (Sep 21); the reaction starts at the next open.
VSTM chart →
